Nucynta 2015 report
Nucynta 2015 U.S. PROMOTIONAL AUDIT REPORT
Published July 2016 • 31 Pages
The 5 Key Questions Addressed by this Report:
- How many physicians were reached by Nucynta through personal promotion in 2015 and how does this compare to its peer set in the Neuropathic Pain and Pain – Opioids markets?
- What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
- How does Depomed and J&J’s depth of coverage vary within key specialties (e.g., Anesthesiology, Physical Medicine and Rehabilitation, Family Medicine, Neurology, Pain Medicine, Internal Medicine, and Orthopedic Surgery) and how does this compare to its peers and the overall set of rep-accessible physicians?
- How often are physicians receiving paid meals for Nucynta throughout the year (e.g., monthly, quarterly, annually)?
- Who were the most detailed prescribers and top paid speakers/consultants for Nucynta in 2015?
Data Sources and Methodology:
- MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, 30 months of longitudinal data is available – covering payments to more than 800,000 U.S. healthcare professionals.
- Over 22,300 paid interactions across 7,800 physicians made on behalf of Nucynta were carefully examined to support our analysis. In addition, interaction data from 13 peer products (e.g. Abstral, Butrans, Embeda, Fentora, Hysingla ER, Ionsys, Lazanda, Lyrica, Opana, OxyContin, Subsys, Xartemis XR, and Zohydro ER) was leveraged to provide benchmarking and market insights.